Pancreatic cancer may thus present an opportunity for IgE immunotherapy, taking advantage of the long tissue retention and potential for prolonged immune surveillance of this class, and the ability of IgE to direct macrophage-mediated tumour cell killing, and potentially antigen presentation and repolarisation of tumour supportive M2-like macrophage subsets. The gene discussed is IGHE; the disease is pancreatic neoplasm.